Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials

被引:0
|
作者
Rooney, Michael K. [1 ]
Sharifi, Bahareh [1 ]
Ludmir, Ethan B. [1 ]
Fuller, Clifton D. [1 ]
Warner, Jeremy L. [2 ,3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, 231 Elmgrove Ave,PRB 777, Providence, RI 02906 USA
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Altmetric Attention Scores (Altmetrics) are real-time measures of scientific impact and attention through various public outlets, including news, blogs, and social media. Herein, we aimed to describe and characterize the relationship between Altmetrics, conventional impact metrics, and features of published cancer clinical trials.METHODS We identified two-arm phase III cancer randomized clinical trials with a superiority end point and publication date between 2015 and 2020 from HemOnc and tabulated the following data: Altmetric, study positivity, US Food and Drug Administration (FDA) registration trial status, cancer site/category, treatment context (curative or palliative), trial design, primary end point type, experimental/control arm modality, and journal tier. We further collected conventional bibliometrics including the number of citations and relative citation ratio (RCR) for all published studies. Multiple linear regression modeling identified clinical trial factors predictive of Altmetrics, with alpha = .05 defining statistical significance.RESULTS Altmetrics were found for 681 (98%) of 698 publications, with a median score of 38.5 (IQR, 13-132.8). FDA registration studies (beta [95% CI], 84.7 [48.8 to 120.6]; P < .001), studies reporting on curative (as opposed to palliative) interventions (-29 [-53.7 to -4.4]; P = .02), genitourinary trials (73.2 [28.1 to 118.2]; P = .001), studies published in tier 1 journals (P < .001), and those with an increased number of citations per year (0.81 [0.66 to 0.95]; P < .001) were significantly associated with increased engagement as measured by Altmetrics. Furthermore, there was a strong correlation between all collected bibliometrics and Altmetrics (R2 = 0.63, 0.68, and 0.67; P < .001 for citation count, citations per year, and RCR, respectively).CONCLUSION FDA registration trials describing curative interventions, studies published in traditionally defined high-impact journals, and genitourinary trial publications tend to have the greatest Altmetrics. We observed a strong relationship between Altmetrics and conventional bibliometrics. The significance and consequences of these relationships warrant further investigation.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
    Yao, Yanhong
    Liu, Zhentao
    Zhang, Hua
    Li, Jian
    Peng, Zhi
    Yu, Jinyu
    Cao, Baoshan
    Shen, Lin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [32] Absolute benefits of experimental medical therapies in phase III randomized clinical trials (RCTs) in breast and colorectal cancer
    Seruga, B.
    Hertz, P. C.
    Wang, L.
    Booth, C. M.
    Krzyzanowska, M.
    Cescon, D. W.
    Tannock, I. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Reporting of serious toxicities of targeted cancer drugs in published reports of randomized phase III clinical trials (RCTs)
    Seruga, B.
    Sterling, L.
    Wang, L.
    Tannock, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Do early phase trials predict clinical efficacy in subsequent phase III biomarker-enriched randomized trials?
    Udayakumar, Suji
    Thomson, Sasha
    Razak, Albiruni Ryan Abdul
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Phase II and III clinical trials of toremifene for metastatic breast cancer
    Vogel, CL
    ONCOLOGY-NEW YORK, 1998, 12 (03): : 9 - 13
  • [36] ECONOMIC-ANALYSIS IN PHASE-III CLINICAL CANCER TRIALS
    BENNETT, CL
    ARMITAGE, JL
    BUCHNER, D
    GULATI, S
    CANCER INVESTIGATION, 1994, 12 (03) : 336 - 342
  • [37] Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer
    de Gramont, Aimery
    Chibaudel, Benoist
    Bonnetain, Franck
    Dumont, Sarah
    Larsen, Annette K.
    Andre, Thierry
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (03) : 292 - 301
  • [38] Performance status restriction in phase III cancer clinical trials.
    Kouzy, Ramez
    Jaoude, Joseph Abi
    Mainwaring, Walker
    Lin, Timothy
    Miller, Austin B.
    Jethanandani, Amit
    Espinoza, Andres F.
    Taniguchi, Cullen M.
    Ludmir, Ethan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Factors associated with participation in breast cancer treatment clinical trials
    Avis, NE
    Smith, KW
    Link, CL
    Hortobagyi, GN
    Rivera, E
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1860 - 1867
  • [40] Factors predicting missing instruments in three cancer randomized clinical trials
    Michael J. Palmer
    Harriet Richardson
    Dongsheng Tu
    Michael Brundage
    Quality of Life Research, 2021, 30 : 2219 - 2234